tbuckley/cabot-search huggingface dataset:
Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study
Authors: Lasse Hjort Jakobsen, Martin Bøgsted, Peter de Nully Brown, Bente Arboe, Judit Jørgensen, Thomas Stauffer Larsen, Maja Bech Juul, Lene Schurmann, Linda Højberg, Olav Jonas Bergmann, Therese Lassen, Pär Lars Josefsson, Paw Jensen, Hans Erik Johnsen, Tarec Christoffer El-Galaly
Journal: Journal of Clinical Oncology (2017)

Purpose The general outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important information for patients and for planning post-treatment follow-up. The purpose of this study was to evaluate the survival of patients with DLBCL in remission compared with a matched general population. Methods A total of 1,621 patients from the Danish Lymphoma Registry who were newly diagnosed with DLBCL between 2003 and 2011 were included in this study. All patients were ≥ 16 years of age at diagnosis and had achieved complete remission or complete remission unconfirmed after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP–like therapy. Results The 5-year post-treatment DLBCL survival was inferior to survival in the matched general population (78%; 95% CI, 76 to 80; v 87%; standardized mortality ratio, 1.75; P &lt; .001). Excess mortality was present but reduced for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized mortality ratio, 1.27; P &lt; .001). In age-stratified analyses, the survival of patients &lt; 50 years of age was normalized to the general population after achieving pEFS24 ( P = .99). During the first 8 years after pEFS24, the average loss of lifetime was 0.31 mo/y (95% CI, 0.11 to 0.50 mo/y). Excess mortality diminished when analyzing death from lymphoma as competing event to death from other causes, suggesting that early and late relapse is responsible for increased mortality in patients with DLBCL. Conclusion Although this population-based study does not support complete normalization of survival for patients with DLBCL achieving pEFS24, the estimated loss of residual lifetime was low for patients in continuous remission 2 years after ending treatment. Therefore, pEFS24 is an appealing and relevant milestone for patient counseling and could be a surrogate end point in clinical trials.
Comparative 2-Arm Study for Acute Graft-Versus-Host Disease; Antithymocyte Globulin Is More Effective Than Mycofenolate Mofetil on Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation from Mismatched Unrelated Donors.
Authors: Woo-Sung Min, Heeje Kim, Byoung-Sik Cho, Sung-Yong Kim, Ki-Sung Eom, Chang-Ki Min, Seok Lee, Jong-Wook Lee, Chong-Won Park, Chun-Choo Kim
Journal: Blood (2006)
Next Generation Sequencing Spectratyping (NGS-S) Comprehensively Monitors T Cell Receptor Diversity in Children with T Cell Abnormalities
Authors: Pina Fanny Ida Krell, Stephan Weber, Susanne Reuther, Michael Gombert, Thomas Keller, Friedhelm R. Schuster, Corinna Asang, Jens Stoye, Arndt Borkhardt, Ute Fischer
Journal: Blood (2011)
Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3)
Authors: Rozovski Uri, David Harris, Ping Li, Zhiming Liu, Srdana Grgurevic, Susan Lerner, Matthew Martinez, William G. Wierda, Michael Keating, Zeev Estrov
Journal: Blood (2012)
Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients
Authors: Francesca Gay, Alessandra Larocca, P.W. Wijermans, Sara Bringhen, Tommasina Guglielmelli, Martijn R. Schaafsma, Giulia Benevolo, Vincenzo Callea, Luca Baldini, Fortunato Morabito, Mariella Grasso, Giuseppe Torelli, Manuela Rizzo, Monica Galli, Grazia Sanpaolo, Clotilde Cangialosi, Paola Omedè, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo
Journal: Blood (2010)
IgH and TCRgamma Gene Rearrangements, Cyclin A1 and HOXA9 Gene Expression in Biphenotypic Acute Leukemias.
Authors: Mirna Golemovic, Mirna Sucic, Renata Zadro, Sanja Davidovic Mrsic, Mirta Mikulic, Ljubica Rajic, Boris Labar, Drago Batinic
Journal: Blood (2005)
Excessive Nitric Oxide Production of CGD Neutrophils Induces the Down-Regulation of NOS3 and EDN1 Expression in Human Endothelial Cells
Authors: Akari Utsunomiya, Miyuki Tsumura, Norioki Ohno, Mizuka Miki, Satoshi Okada, Hiroshi Kawaguchi, Kazuhiro Nakamura, Masao Kobayashi
Journal: Blood (2014)
NOD2/CARD15 Mutations Associate with Transplant Related Mortality and GvHD in HLA-Identical Sibling Transplants: Detailed Analysis of Single SNPs in 211 Recipient/Donor Pairs.
Authors: Ernst Holler, Gerhard Rogler, Joachim Hahn, Hans Herfarth, Julia Brenmoehl, Guenther Eissner, Anne M. Dickinson, Graham Jackson, Hildegard Greinix, Gerhard Fischer, Daniel Wolff, Beate Steiner, Joerg Marienhagen, Reinhard Andreesen
Journal: Blood (2004)
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.
Authors: Maristella Bianconi, Mario Scartozzi, Luca Faloppi, Riccardo Giampieri, Elena Maccaroni, Alessandro Bittoni, Michela Del Prete, Cristian Loretelli, Laura Belvederesi, Alessandro Conti, Daniele Minardi, Luciano Burattini, Rodolfo Montironi, Stefano Cascinu
Journal: Journal of Clinical Oncology (2012)

380 Background: Metastatic renal cell carcinoma (mRCC) still represents a medical challenge in cancer therapy. In recent years the introduction of new targeted therapies has radically changed the approach to the disease and patients outcome. Currently the therapeutic strongholds are TKIs directed against the VEGF family. The aim of our study is to evaluate the potential predictive and prognostic role of VEGF and VEGFR polymorphisms, in determining the clinical outcome of mRCC patients receiving first-line sunitinib. Methods: 41 histologic samples (biopsies and surgical specimens) of mRCC patients were tested for VEGF-A, VEGF-C and VEGFR-1,2,3 single nucleotide polymorphisms (SNPs). Patients progression free survival (PFS) and overall survival (OS) were analyzed for first line treatment. Results: VEGF AIV rs833061 C&gt;T polymorphism was statistically significant in PFS (17 months for C vs 4 months for T; P = 0.0029) and OS (35.93 months for C vs 11 months for T; P = 0.0267). VEGF AV rs699947 A&gt;C was statistically significant for PFS (17 months for A vs 3.97 months for C; P = 0.0023) and OS (35.93 months for A vs 10.98 for C; P = 0.0272). VEGF AVI rs2010963 G&gt;C was significant in PFS (16.98 months for G vs 4.65 for G/C vs 2.73 for C; P = 0.0188). VEGR3 III rs6877011 C&gt;G was significant in PFS (8.22 months for C vs 2.22 for C/G; P = 0.0361) and OS (35.93 months for C vs 12.08 for C/G; P = 0.0183). Conclusions: In our analysis patients with C polymorphism of rc833061 , A polymorphism rs699947 and G polymorphism of rs2010963 seem to have a better PFS and OS in first line. These polymorphisms of the VEGF-A gene are probably connected with a better control of the neoangiogenesis process during TKIs therapy, maybe leading to vasculature normalization. Patients with C polymorphism of rs6877011 seem equally to have a favourable impact in first line therapy. VEGFR-3 role is still matter of debate but seems to be involved in vessels sprouting and architecture.
CD38 and ZAP-70 Mark Chronic Lymphocytic Leukemia (CLL) Cells with High Migratory Potential and Regulate Chemotaxis.
Authors: Silvia Deaglio, Semra Aydin, Tiziana Vaisitti, Luciana Bergui, Giovanni D’Arena, Lisa Bonello, Paola Omedé, Giovanna Chiorino, Dimitar Efremov, Fabio Malavasi
Journal: Blood (2007)
Curing Multiple Myeloma (MM) with High-Risk Features Defined by Metaphase Cytogenetic Abnormalities (CA), High LDH (&gt;300U/L) and Gene Expression Profiling (GEP)-70 Score &gt;=+o.66
Authors: Bart Barlogie, Alan Mitchell, Frits van Rhee, Sarah Waheed, Saad Z Usmani, Monica Grazziutti, Alejandro Restrepo, Al-Ola Abdallah, Nisar Ahmad, Senu Apewokin, Shebli Atrash, Aziz Bakhous, Sajjad Haider, Surachit Kumar, Jameel Muzaffar, Zainab Shahid, John Crowley
Journal: Blood (2012)
A specific dietary intervention to restore brain structure and function after ischemic stroke
Authors: Maximilian Wiesmann, Bastian Zinnhardt, Dirk Reinhardt, Sarah Eligehausen, Lydia Wachsmuth, Sven Hermann, Pieter J Dederen, Marloes Hellwich, Michael T Kuhlmann, Laus M Broersen, Arend Heerschap, Andreas H Jacobs, Amanda J Kiliaan
Journal: Theranostics (2017)

Occlusion of the middle cerebral artery (MCAo) is among the most common causes of ischemic stroke in humans.Cerebral ischemia leads to brain lesions existing of an irreversibly injured core and an ischemic boundary zone, the penumbra, containing damaged but potentially salvageable tissue.Using a transient occlusion (30 min) of the middle cerebral artery (tMCAo) mouse model in this cross-institutional study we investigated the neurorestorative efficacy of a dietary approach (Fortasyn) comprising docosahexaenoic acid, eicosapentaenoic acid, uridine, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium as therapeutic approach to counteract neuroinflammation and impairments of cerebral (structural+functional) connectivity, cerebral blood flow (CBF), and motor function.Male adult C57BL/6j mice were subjected to right tMCAo using the intraluminal filament model.Following tMCAo, animals were either maintained on Control diet or switched to the multicomponent Fortasyn diet.At several time points after tMCAo, behavioral tests, and MRI and PET scanning were conducted to identify the impact of the multicomponent diet on the elicited neuroinflammatory response, loss of cerebral connectivity, and the resulting impairment of motor function after experimental stroke.Mice on the multicomponent diet showed decreased neuroinflammation, improved functional and structural connectivity, beneficial effect on CBF, and also improved motor function after tMCAo.Our present data show that this specific dietary intervention may have beneficial effects on structural and functional recovery and therefore therapeutic potential after ischemic stroke.
Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia
Authors: Teena Bhatla, Roy Blum, Jinhua Wang, Courtney L Jones, Debra J. Morrison, Elizabeth A Raetz, Michael J. Burke, Patrick Brown, Richard C. Harvey, Cheryl L. Willman, Mignon Loh, Stephen P. Hunger, William L. Carroll
Journal: Blood (2014)
Dysregulated Apurinic/Apyrimidinic Endonucleases (Ape1 and Ape2) Lead to Genetic Instability in Multiple Myeloma.
Authors: Masood A. Shammas, Hemant Koley, Sima Shah, Ramesh B. Batchu, Pierfrancesco Tassone, Kenneth C. Anderson, Nikhil C. Munshi
Journal: Blood (2004)
Lenalidomide Alone and in Combination with Rituximab Enhances NK Cell Immune Synapse Formation in Chronic Lymphocytic Leukemia (CLL) Cells in Vitro through Activation of Rho and Rac1 GTPases.
Authors: Svetlana Gaidarova, JianWu Li, Laura G Corral, Emilia Glezer, Peter H Schafer, Weilin Xie, Antonia Lopez-Girona, Bruce D. Cheson, Brydon Bennett
Journal: Blood (2009)
Additional important research priorities for bronchiectasis in China
Authors: Wei-jie Guan, Yong-hua Gao, Jing-jing Yuan, Rong-chang Chen, Nan-shan Zhong
Journal: European Respiratory Journal (2017)

We highly appreciate the laudable desire of the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) [1] to provoke research interests and develop study protocols to investigate bronchiectasis, a disease which has not yet received sufficient attention worldwide, particularly in China. China is a major developing country with a large population; however, there is a lack of epidemiological investigations detailing the prevalence or incidence of bronchiectasis. While we totally concur with the recommendations from European experts, we feel that additional priorities in bronchiectasis should be highlighted for future research in China. Aetiology, Chinese medicine, phenotyping, fertility and comorbidities of bronchiectasis should be studied in China <http://ow.ly/tiJl304s5j0> Author contributions: W.J.G., Y.H.G. and J.J.Y. drafted the manuscript; R.C.C. and N.S.Z. critically reviewed the manuscript and approved final submission.
The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling
Authors: Peng Han, Jing-wen Li, Bo-miao Zhang, Jia-chen Lv, Yong-min Li, Xin-yue Gu, Zhi-wei Yu, Yun-he Jia, Xue-feng Bai, Li Li, Yan-long Liu, Bin-bin Cui
Journal: Molecular Cancer (2017)

With more than 600,000 mortalities each year, colorectal cancer (CRC) is the third most commonly diagnosed type of cancer worldwide. Recently, mechanisms involving noncoding RNAs have been implicated in the development of CRC. We examined expression levels of lncRNA CRNDE and miR-181a-5p in 64 cases of CRC tissues and cell lines by qRT-PCR. Gain-of-function and loss-of-function assays were performed to examine the effect of CRNDE and miR-181a-5p on proliferation and chemoresistance of CRC cells. Using fluorescence reporter and western blot assays, we also explored the possible mechanisms of CRNDE in CRC cells. In this study, we found that the expression levels of the CRNDE were upregulated in CRC clinical tissue samples. We identified microRNA miR-181a-5p as an inhibitory target of CRNDE. Both CRNDE knockdown and miR-181a-5p overexpression in CRC cell lines led to inhibited cell proliferation and reduced chemoresistance. We also determined that β-catenin and TCF4 were inhibitory targets of miR-181a-5p, and that Wnt/β-catenin signaling was inhibited by both CRNDE knockdown and miR-181a-5p overexpression. Significantly, we found that the repression of cell proliferation, the reduction of chemoresistance, and the inhibition of Wnt/β-catenin signaling induced by CRNDE knockdown would require the increased expression of miR-181a-5p. Our study demonstrated that the lncRNA CRNDE could regulate the progression and chemoresistance of CRC via modulating the expression levels of miR-181a-5p and the activity of Wnt/β-catenin signaling.
Graft-Versus-Host Disease Prophylaxis Using Tacrolimus + Mycophenolate in Cord Blood Transplantation for Elderly; Impact of Mycophenolate Dosing
Authors: Naoyuki Uchida, Hisashi Yamamoto, Yuki Taya, Hikari Ota, Aya Nishida, Taichi Ikebe, Sachi Tainosho, Muneyoshi Kimura, Kazuya Ishiwata, Masanori Tsuji, Hideki Araoka, Yuki Asano-Mori, Koji Izutsu, Kazuhiro Masuoka, Shigeyoshi Makino, Akiko Yoneyama, Atsushi Wake, Shuichi Taniguchi
Journal: Blood (2011)
Vaccination of B-CLL Patients with Autologous Dendritic Cells Results in Immunological and Clinical Responses.
Authors: Iwona Hus, Michael Schmitt, Jacek Tabarkiewicz, Sebastian Radej, Agnieszka Bojarska-Junak, Kamila Wojas, Anita Schmitt, Krzysztof Giannopoulos, Anna Dmoszynska, Jacek Rolinski
Journal: Blood (2007)
Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
Authors: Michael R Rossi, Scott Newman, Ajay K. Nooka, Jonathan L. Kaufman, Nizar J. Bahlis, Paola Neri, Shannon M. Matulis, Leon Bernal-Mizrachi, Vikas A. Gupta, Anjana Varma, Malania Wilson, Juliana DaSilva, Robert Benjamin Isett, Linsheng Zhang, Debra Saxe, Karen P. Mann, David L Jaye, Lawrence H. Boise, Sagar Lonial
Journal: Blood (2013)
Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom’s Macroglobulinemia (WM).
Authors: Zachary R. Hunter, Xavier Leleu, Daniel D. Santos, Susannah Hamilton, Sigitas Verselis, Edward A. Fox, Iqbal Grewal, Steven Treon
Journal: Blood (2005)
Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL.
Authors: Jennifer O’Neil, Joelle Tchinda, Alejandro Gutierrez, Lisa Moreau, Keith McKenna, Richard Maser, Kwok-Kin Wong, Wen-shu Wu, Ronald DePinho, Lynda Chin, Charles Lee, A. Thomas Look
Journal: Blood (2006)
An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.
Authors: Oliver W. Press, Joseph Unger, David Maloney, Rita M. Braziel, Michael LeBlanc, Thomas Grogan, Thomas P. Miller, Richard I. Fisher
Journal: Blood (2005)
Impact of Hyperbaric Oxygen Treatment on Time to Transfusion Independency Post-UCB Transplant
Authors: Amy Rose Cantilena, Tara L. Lin, Siddhartha Ganguly, Leyla Shune, Anurag K. Singh, Sunil Abhyankar, Jonathan Mahnken, Dennis Allin, Joseph McGuirk, Omar S. Aljitawi
Journal: Blood (2015)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Authors: Hashim U Ahmed, Ahmed El-Shater Bosaily, Louise C Brown, Rhian Gabe, Richard Kaplan, Mahesh K Parmar, Yolanda Collaco-Moraes, Katie Ward, Richard G Hindley, Alex Freeman, Alex P Kirkham, Robert Oldroyd, Chris Parker, Mark Emberton
Journal: The Lancet (2017)

Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (MP-MRI) used as a triage test might allow men to avoid unnecessary TRUS-biopsy and improve diagnostic accuracy.
STUDIES ON VIRULENCE
Authors: Lloyd D. Felton
Journal: The Journal of Experimental Medicine (1932)

The growth of a virulent Type I pneumococcus in an automatic transfer device on a medium which aerobically maintains virulence results in a decrease in the presence of pure oxygen or pure carbon dioxide, but in no change in the presence of nitrogen. Whereas partial pressures of oxygen, that is 5 parts with 95 parts nitrogen by volume, and 10 parts with 90 parts nitrogen, resulted in a decrease in virulence, with 20 parts oxygen and 80 parts nitrogen, the decrease was almost negligible. Media which under aerobic conditions failed to furnish suitable constituents for maintenance of virulence, that is spleen, aminoid peptone, powdered milk, beef infusion, whole rabbit, and rabbit muscle, also failed under nitrogen. Media from whole guinea pig kept the organism virulent for 246 transfers under nitrogen, but with some decrease. Media made from discard mice, survivors of pneumococcus infection, furnished conditions under nitrogen, which caused first a decrease of virulence, but later after 246 transfers, a restoration to a more virulent state. Gradual increase in temperature over a period of 10 days from 36.5 degrees C. to 42 degrees C. in a sample of medium, which was otherwise suitable for maintenance of virulence under aerobic conditions, resulted in a decrease in virulence.
Essential Thrombocythemia in Patients with Platelet Counts below 600×109/L: Applicability of the 2008 World Health Organization Diagnostic Criteria Proposal
Authors: Mi Kwon, Santiago Osorio Prendes, Carolina Muñoz, Jose Manuel Sanchez, Monica Ballesteros, Isabel Perez Sanchez, Victor Echeverria, Magdalena Mayayo, Javier Menarguez, Antonio Escudero Soto, Jose Luis Diez-Martin
Journal: Blood (2008)
High Risk of Acute Myeloid Leukemia in Individuals with NAD(P)H:Quinone Oxidoreductase 1 (NQO1) and Cytochrome P450 A1 (CYP1A1) Gene Defects.
Authors: Gabriela G. Yamaguti, Gustavo J. Lourenco, Fernando F. Costa, Carmen S.P. Lima
Journal: Blood (2007)
Reply
Authors: Àngels Escorsell, Oana Pavel, Andrés Cárdenas, Rosa Morillas, Elba Llop, Càndid Villanueva, Juan Càrlos Garcia‐Pagan, Jaime Bosch
Journal: Hepatology (2017)

Potential conflict of interest: Dr. Morillas advises for and is on the speakers' bureau for Gilead, AbbVie, Merck, and Bristol‐Myers Squibb. Dr. Escorsell received grants from Vital Therapies. Dr. Garcia‐Pagan received grants from Gore, Exalenz, and Novartis. Reply: We sincerely thank Gundling et al. for their letter. We totally agree with them that migration after deployment of self‐expanding esophageal covered metal stents (SX‐ELLA Danis) is not an uncommon complication of this device. In fact, some researchers reported an incidence of stent migration as high as 25%.1 However, migration by itself should not be considered as an adverse event or equivalent to treatment failure—unless it gives rise to a specific complication or rebleeding. Of course, in our study, we considered the possibility of immediate stent migration. Accordingly, surveillance chest x‐ray was routinely scheduled for its detection immediately after and at 12 hours following the procedure. This was also the very reason for which we allowed repositioning or replacement of the esophageal stent during the first 24 hours after its deployment. We chose this time lapse because of the recognized high risk of rebleeding during the first 24 hours, a risk that is known to progressively decrease thereafter.4 As mentioned in the article, one of our patients randomized to receive the esophageal stent actually was treated by a Sengstaken tube because of a defect in the stent delivery system (rupture of the gastric balloon). In addition, 2 patients experienced stent migration, which was detected in the plain chest x‐ray performed immediately after stent deployment. In both instances, stent migration was immediately corrected, by repositioning the stent in 1 case and by removing the migrated stent and placement of a second one in the other case. These were considered technical problems rather than complications, given that none were associated with failure in controlling bleeding or with the development of clinical complications. Admitedly, we do not know whether such an early detection of the stent migration in our 2 patients and its rapid resolution prevented the development of subsequent serious complications. Therefore, we agree with Gundling et al. that migration after the deployment of self‐expanding esophageal metal stents represents a potential complication in the treatment of bleeding esophageal varices. Nevertheless, its consequences may be mitigated by scheduling a plain chest x‐ray immediately after stent deployment and periodically thereafter, because this allows its early recognition and resolution.
Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma
Authors: Yuko Tanaka, Seiichi Okabe, Tetsuzo Tauchi, Yoshikazu Ito, Tomohiro Umezu, Junko H Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2013)
Abstract 4605: Prolonged Use of Clopidogrel Reduces Death and Myocardial Infarction Following Drug Eluting Stent but Not Bare Metal Stent Placement: The VA DES Study
Authors: David P Faxon, Scott Kinlay, Rohini K Hernandez, J. Michael Gaziano, Elizabeth Lawler
Journal: Circulation (2009)

The use of clopidogrel and ASA has been recommended for up to one year after DES placement but the value beyond this time is controversial. To evaluate this issue, all patients in the VA healthcare...
Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation
Authors: Erez Dror, Elise Dalmas, Daniel T Meier, Stephan Wueest, Julien Thévenet, Constanze Thienel, Katharina Timper, Thierry M Nordmann, Shuyang Traub, Friederike Schulze, Flurin Item, David Vallois, Francois Pattou, Julie Kerr-Conte, Vanessa Lavallard, Thierry Berney, Bernard Thorens, Daniel Konrad, Marianne Böni-Schnetzler, Marc Y Donath
Journal: Nature Immunology (2017)
Fludarabine, Cytarabine, Daunoxome Plus Dasatinib Has High Efficacy with an Acceptable Toxicity Profile As Either Consolidation or Salvage Regimen in Adult Philadelphia Positive Acute Lymphoblastic Leukemia Patients
Authors: Giordana Pastori, Fabio Guolo, Daniela Guardo, Paola Minetto, Marino Clavio, Maurizio Miglino, Livia Giannoni, Elisa Coviello, Filippo Ballerini, Federica Galaverna, Annalisa Kunkl, Nicoletta Colombo, Raffaella Grasso, Roberto Massimo Lemoli, Marco Gobbi
Journal: Blood (2015)